EYPT - EyePoint Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.95
-0.04 (-1.34%)
At close: 4:00PM EDT

2.95 -0.00 (-0.03%)
After hours: 4:11PM EDT

Stock chart is not supported by your current browser
Previous Close2.99
Open2.97
Bid2.85 x 900
Ask3.06 x 800
Day's Range2.82 - 3.09
52 Week Range0.93 - 3.94
Volume735,489
Avg. Volume535,909
Market Cap219.81M
Beta (3Y Monthly)-1.97
PE Ratio (TTM)N/A
EPS (TTM)-1.15
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • GlobeNewswire12 hours ago

    EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ to be Presented at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting

    - Five oral abstracts to be presented at annual meeting and subspecialty days –-24-month follow up YUTIQ data to be highlighted at a breakthrough presentation- WATERTOWN,.

  • EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq
    Zacksyesterday

    EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq

    EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.

  • EyePoint Pharmaceuticals (EYPT) Catches Eye: Stock Jumps 6.8%
    Zacks2 days ago

    EyePoint Pharmaceuticals (EYPT) Catches Eye: Stock Jumps 6.8%

    EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Market Exclusive3 days ago

    Stock Market News Daily Roundup October 15

    Netflix, PayPal, IBM, Others Reporting This Week Many key companies are set to report earnings this week. Bank of America has reported its quarterly results today while Morgan Stanley, Goldman Sachs, Netflix, United Airlines, Johnson & Johnson, BlackRock, and IBM will report earnings on Tuesday. On Wednesday, earnings will be released by United Rentals and […] The post Stock Market News Daily Roundup October 15 appeared first on Market Exclusive.

  • MarketWatch3 days ago

    EyePoint Pharma shares jump on FDA approval of Yutiq implant

    EyePoint Pharmaceuticals Inc. shares soared 8% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has approved its Yutiq implant for the treatment of uveitis, a leading cause of blindness. Yutiq is a micro-insert that is designed to release fluocinolone acetonide over a three-year period and that can be administered in a doctor's office. :Chronic non-infectious uveitis affecting the posterior segment of the eye is the third leading cause of blindness in the U.S.," Chief Executive Nancy Lurker said in a statement. The company is expecting to launch the product in the first quarter of 2019. EyePoint shares have gained 199% in 2018, while the S&P 500 has gained 3.5%.

  • GlobeNewswire3 days ago

    EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced today that the U. S. Food and Drug Administration (FDA) has approved YUTIQ™ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes the Company’s Durasert™ drug delivery technology and is a non-bioerodible intravitreal micro-insert in a drug delivery system containing 0.18 mg fluocinolone acetonide, designed to release consistently over 36 months.

  • Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options
    Zacks17 days ago

    Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options

    Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.

  • GlobeNewswire17 days ago

    EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has received proceeds of $28.9 million from the exercise of warrants by EW Healthcare Partners, Rosalind Advisors, Inc., and another accredited investor (Second Tranche Investors). “We are pleased to receive the continued support of  EW Healthcare Partners,  Rosalind Advisors and our other investors, for our innovative pipeline of ocular disease products,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals.

  • GuruFocus.comlast month

    US Stocks Lower on Wednesday

    EyePoint Pharmaceuticals down more than 3% after reporting results

  • EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
    Zackslast month

    EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

    EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -111.11% and 6.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    EyePoint Pharmaceuticals: Fiscal 4Q Earnings Snapshot

    The Watertown, Massachusetts-based company said it had a loss of 62 cents per share. Losses, adjusted for non-recurring costs, were 19 cents per share. The drug delivery technology company posted revenue ...

  • GlobeNewswirelast month

    EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress

    -Substantial progress made in the Company’ s accelerated transformation into a commercial entity. -YUTIQ™ PDUFA date of November 5, 2018. -Commercial preparations underway for launch of DEXYCU™ in the ...

  • GlobeNewswirelast month

    EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors

    EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company’s Board of Directors has elected Göran Ando, M.D., as its next Chairman of the Board. As part of this transition, David J. Mazzo, Ph.D., will step-down as Non-Executive Chairman, but will remain on the Board and will continue to serve as Chair of the Compensation Committee. “We are pleased to have Dr. Ando serve as our Chairman of the Board as we continue our transition into a commercial-stage specialty pharmaceuticals company,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals.

  • ACCESSWIRElast month

    Healthcare Stocks Take Center Stage In September

    CORAL GABLES, FL / ACCESSWIRE / September 6, 2018 / The healthcare industry has become one of the fastest growing industries in the world. The growing advancements in the industry are steadily contributing towards its market growth. According to the findings of the latest study, expansion in the current market, new product development, and improving operational effectiveness are the top three priorities for the healthcare companies over the next six months.

  • Benzingalast month

    The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Sept. 5) Aptinyx Inc (NASDAQ: APTX ) Avanos Medical Inc (NYSE: AVNS ...

  • GlobeNewswirelast month

    EyePoint Pharmaceuticals Secures Pass-through Payment Status and Assignment of C-Code for DEXYCU™

    EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through status and reimbursement through a C-code for DEXYCUTM (dexamethasone intraocular suspension) 9%. DEXYCU is the Company’s U.S. Food and Drug Administration (FDA) approved product for the treatment of postoperative inflammation that is administered as a single intraocular dose at the end of ocular surgery. “The receipt of pass-through status and the assignment of a C-code from CMS marks another important step forward in our commercialization preparation for DEXYCU,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals.

  • GlobeNewswirelast month

    EyePoint Pharmaceuticals Announces Fiscal 2018 Fourth Quarter & Full Year Financial Results Release Date and Conference Call Information

    WATERTOWN, Mass., Sept. 05, 2018-- EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results ...

  • EyePoint Pharmaceuticals (EYPT) Q4 Earnings Preview: What to Know Ahead of the Release
    Zackslast month

    EyePoint Pharmaceuticals (EYPT) Q4 Earnings Preview: What to Know Ahead of the Release

    EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences

    WATERTOWN, Mass., Aug. 28, 2018-- EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that ...

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of John Weet, Ph.D. as Senior Vice President, Regulatory Affairs & Quality. Dr. Weet brings to EyePoint over 40 years of experience in regulatory affairs. “We are delighted to welcome Dr. Weet, a proven regulatory affairs executive, to the growing EyePoint team,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals.

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported the grant of inducement awards to David Price, EyePoint’s newly appointed Chief Financial Officer. The Compensation Committee approved the awards on July 31, 2018 as an inducement material to Mr. Price’s entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

  • GlobeNewswire3 months ago

    EyePoint Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference

    WATERTOWN, Mass., Aug. 02, 2018-- EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that ...

  • GlobeNewswire3 months ago

    EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officer

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of David Price as Chief Financial Officer, effective immediately. In this role, Mr. Price will oversee and lead the Company’s financial and capital markets activities. Mr. Price brings to EyePoint more than 25 years of financial experience in the healthcare, investment banking and accounting industries.

  • GlobeNewswire3 months ago

    EyePoint Pharmaceuticals Announces Presentation of Data Highlighting YUTIQ™ for Posterior Segment Uveitis at the 36th Annual Scientific Meeting of the American Society of Retina Specialists

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of twelve month efficacy and safety data supporting the Company's YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for noninfectious posterior segment uveitis. The data were presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Vancouver, BC, Canada. "Data from the Phase 3 program continue to support the potential for YUTIQ™ to serve as an effective and safe therapy in the thousands of patients suffering from noninfectious posterior segment uveitis," said Nancy Lurker, President and Chief Executive Officer.